Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Habib, Hamidi"'
Autor:
Aditi Qamra, Hartmut Koeppen, Fabrice Barlesi, Federico Cappuzzo, Martin Reck, Mark A Socinski, Marcus Ballinger, Robert M Jotte, Barzin Nabet, Minu K Srivastava, Soren Muller, Tianshi Lu, Howard West, Habib Hamidi, Assaf Amitai, David S Shames
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/a3510600342247d7b4bbe2442738c4b7
Autor:
Sandy Wong, Habib Hamidi, Luciano J. Costa, Selma Bekri, Natalia Neparidze, Ravi Vij, Tina G. Nielsen, Aparna Raval, Rajan Sareen, Elisabeth Wassner-Fritsch, Hearn J. Cho
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Multiple myeloma (MM) remains incurable, and treatment of relapsed/refractory (R/R) disease is challenging. There is an unmet need for more targeted therapies in this setting; deep cellular and molecular phenotyping of the tumor and microenvironment
Externí odkaz:
https://doaj.org/article/3656f8cc865e43c8abe8cc1709403593
Autor:
Srdan Verstovsek, Lynda Foltz, Vikas Gupta, Robert Hasserjian, Taghi Manshouri, John Mascarenhas, Ruben Mesa, Olga Pozdnyakova, Ellen Ritchie, Ivo Veletic, Katia Gamel, Habib Hamidi, Lyrialle Han, Brian Higgins, Kerstin Trunzer, Marianne Uguen, Dao Wang, Tarec Christoffer El-Galaly, Boyan Todorov, Jason Gotlib
Publikováno v:
Haematologica, Vol 108, Iss 10 (2023)
Pentraxin 2 (PTX-2; serum amyloid P component), a circulating endogenous regulator of the inflammatory response to tissue injury and fibrosis, is reduced in patients with myelofibrosis (MF). Zinpentraxin alfa (RO7490677, PRM-151) is a recombinant for
Externí odkaz:
https://doaj.org/article/853c9266e7f0447385d894bbf77cd11a
Autor:
Kamalakannan Rajasekaran, Xiangnan Guan, Alireza Tafazzol, Habib Hamidi, Martine Darwish, Mahesh Yadav
Publikováno v:
Translational Oncology, Vol 27, Iss , Pp 101559- (2023)
Background: Recent advances in single-cell technologies and an improved understanding of tumor antigens have empowered researchers to investigate tumor antigen-specific CD8+ T cells at the single-cell level. Peptide-MHC I tetramers are often utilized
Externí odkaz:
https://doaj.org/article/2c46d971ad4c4375b7ee0e590ee03894
Immune microenvironment characteristics in multiple myeloma progression from transcriptome profiling
Autor:
Jin Wang, Yi Hu, Habib Hamidi, Cedric Dos Santos, Jingyu Zhang, Elizabeth Punnoose, Wenjin Li
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Multiple myeloma (MM) is characterized by clonal expansion of malignant plasma cells in the bone marrow (BM). Despite the significant advances in treatment, relapsed and refractory MM has not yet been completely cured due to the immune dysfunction in
Externí odkaz:
https://doaj.org/article/a1eba1ba8a9e437bb7efb6f848925dec
Autor:
Charles N. Landen, Luciana Molinero, Habib Hamidi, Jalid Sehouli, Austin Miller, Kathleen N. Moore, Cagatay Taskiran, Michael Bookman, Kristina Lindemann, Charles Anderson, Regina Berger, Tashanna Myers, Mario Beiner, Thomas Reid, Els Van Nieuwenhuysen, Andrew Green, Aikou Okamoto, Carol Aghajanian, Premal H. Thaker, Stephanie V. Blank, Victor K. Khor, Ching-Wei Chang, Yvonne G. Lin, Sandro Pignata
Publikováno v:
Clinical Cancer Research. 29:1698-1707
Purpose: To explore whether patients with BRCA1/2-mutated or homologous recombination deficient (HRD) ovarian cancers benefitted from atezolizumab in the phase III IMagyn050 (NCT03038100) trial. Patients and Methods: Patients with newly diagnosed ova
Autor:
Sandro Pignata, Yvonne G. Lin, Ching-Wei Chang, Victor K. Khor, Stephanie V. Blank, Premal H. Thaker, Carol Aghajanian, Aikou Okamoto, Andrew Green, Els Van Nieuwenhuysen, Thomas Reid, Mario Beiner, Tashanna Myers, Regina Berger, Charles Anderson, Kristina Lindemann, Michael Bookman, Cagatay Taskiran, Kathleen N. Moore, Austin Miller, Jalid Sehouli, Habib Hamidi, Luciana Molinero, Charles N. Landen
PFS by treatment arm according to TMB status (stratified by treatment approach, disease stage, and ECOG PS). A, TMB-low population. B, TMB-high population. CPB, paclitaxel, carboplatin, and bevacizumab.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ab8226269a076ceaa25dfedd6f80336
https://doi.org/10.1158/1078-0432.22725021
https://doi.org/10.1158/1078-0432.22725021
Autor:
Sandro Pignata, Yvonne G. Lin, Ching-Wei Chang, Victor K. Khor, Stephanie V. Blank, Premal H. Thaker, Carol Aghajanian, Aikou Okamoto, Andrew Green, Els Van Nieuwenhuysen, Thomas Reid, Mario Beiner, Tashanna Myers, Regina Berger, Charles Anderson, Kristina Lindemann, Michael Bookman, Cagatay Taskiran, Kathleen N. Moore, Austin Miller, Jalid Sehouli, Habib Hamidi, Luciana Molinero, Charles N. Landen
Purpose:To explore whether patients with BRCA1/2-mutated or homologous recombination deficient (HRD) ovarian cancers benefitted from atezolizumab in the phase III IMagyn050 (NCT03038100) trial.Patients and Methods:Patients with newly diagnosed ovaria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9312f31f3a27a5e8188557bdcc517b4
https://doi.org/10.1158/1078-0432.c.6533182
https://doi.org/10.1158/1078-0432.c.6533182
Autor:
Dennis J. Slamon, Steven M. Dubinett, Manway Liu, Cornelia Quadt, Michael Rugaard Jensen, Emin Avsar, Susan Ide, Wylie Hosmer, Amrita J. Desai, Naeimeh Kamranpour, Sharon Pitts, Judy Dering, Habib Hamidi, Richard S. Finn, Edward B. Garon
PDF - 69K, Supplemental Figure Legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c5cc944f3707f5ad259f84b88e0f28a
https://doi.org/10.1158/1535-7163.22500510
https://doi.org/10.1158/1535-7163.22500510
Autor:
Dennis J. Slamon, Steven M. Dubinett, Manway Liu, Cornelia Quadt, Michael Rugaard Jensen, Emin Avsar, Susan Ide, Wylie Hosmer, Amrita J. Desai, Naeimeh Kamranpour, Sharon Pitts, Judy Dering, Habib Hamidi, Richard S. Finn, Edward B. Garon
Heat shock protein 90 (HSP90) is involved in protein folding and functions as a chaperone for numerous client proteins, many of which are important in non–small cell lung cancer (NSCLC) pathogenesis. We sought to define preclinical effects of the H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::340bde653ea76e976bddef604a102046
https://doi.org/10.1158/1535-7163.c.6536484.v1
https://doi.org/10.1158/1535-7163.c.6536484.v1